<DOC>
	<DOCNO>NCT01644175</DOCNO>
	<brief_summary>Alirocumab ( SAR236553/REGN727 ) fully human monoclonal antibody bind proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) . Primary Objective study : - To demonstrate reduction low-density lipoprotein cholesterol ( LDL-C ) alirocumab add-on therapy stable maximally tolerated daily statin therapy without lipid-modifying therapy ( LMT ) comparison placebo 24 week treatment high cardiovascular ( CV ) risk participant hypercholesterolemia Secondary Objectives : - To evaluate effect alirocumab comparison placebo LDL-C time point - To evaluate effect alirocumab lipid parameter - To evaluate safety tolerability alirocumab</brief_summary>
	<brief_title>Efficacy Safety Alirocumab ( SAR236553/REGN727 ) Versus Placebo Top Lipid-Modifying Therapy Patients With High Cardiovascular Risk Hypercholesterolemia ( ODYSSEY COMBO I )</brief_title>
	<detailed_description>The maximum study duration 62 week per participant , include 2-week screening period , 52-week randomized treatment period , 8-week follow-up period .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Participants hypercholesterolemia establish coronary heart disease ( CHD ) CHD risk equivalent adequately control maximally tolerate daily dose statin without LMT , stable dose least 4 week 6 week prior screen ( Week 2 ) Exclusion criterion : Age &lt; 18 legal age adulthood , whichever great Participants without establish CHD CHD risk equivalent LDLC &lt; 70 mg/dL ( &lt; 1.81 mmol/L ) participant history document cardiovascular disease LDLC &lt; 100 mg/dL ( &lt; 2.59 mmol/L ) participant without history document cardiovascular disease Not stable dose LMT ( include statin ) least 4 week and/or fenofibrate least 6 week , applicable , prior screen visit ( Week 2 ) screen randomization Fasting serum triglyceride &gt; 400 mg/dL ( &gt; 4.52 mmol/L ) The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>